BioCentury
ARTICLE | Company News

Rexahn deal

July 6, 2009 7:00 AM UTC

Rexahn granted an undisclosed "top 20 global pharmaceutical company" an option for an exclusive, worldwide license to develop and commercialize RX-3117. The small molecule nucleoside inhibitor of DN...